List of Excipients in Branded Drug TERBINAFINE HYDROCHLORIDE

Generic Drugs Containing TERBINAFINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Walgreen Company	terbinafine hydrochloride	0363-2083	BENZYL ALCOHOL
Walgreen Company	terbinafine hydrochloride	0363-2083	CETYL ALCOHOL
Walgreen Company	terbinafine hydrochloride	0363-2083	CETYL PALMITATE
Walgreen Company	terbinafine hydrochloride	0363-2083	ISOPROPYL MYRISTATE
Walgreen Company	terbinafine hydrochloride	0363-2083	POLYSORBATE 60
Walgreen Company	terbinafine hydrochloride	0363-2083	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in TERBINAFINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	ALLANTOIN
1	ALOE BARBADENSIS LEAF JUICE POWDER
15	BENZYL ALCOHOL
1	CALCIUM DISODIUM EDTA
42	CELLULOSE, MICROCRYSTALLINE
16	CETYL ALCOHOL

Last updated: August 8, 2026

Terbinafine hydrochloride is a mature generic antifungal with limited compound-patent protection and meaningful commercial opportunity in formulation, delivery, adherence, and consumer convenience. The strongest opportunities are topical products for onychomycosis and dermatomycoses, including alcohol-reduced systems, film-forming solutions, sprays, foams, and nail-directed vehicles. Oral tablets remain low-cost and technically straightforward, but have limited differentiation potential and greater systemic safety considerations.

Terbinafine Hydrochloride Excipient Strategy and Commercial Opportunities

What is the market position of terbinafine hydrochloride?

Terbinafine hydrochloride is an allylamine antifungal used in oral and topical products. It inhibits squalene epoxidase, causing fungal squalene accumulation and ergosterol depletion. The active ingredient is used against dermatophytes and several other fungi, with topical products commonly indicated for tinea pedis, tinea cruris, tinea corporis, and related superficial infections. Oral terbinafine is used primarily for toenail and fingernail onychomycosis caused by dermatophytes.

The reference brand is Lamisil, originally marketed by Novartis. U.S. oral tablets are generally available as 250 mg terbinafine hydrochloride tablets. Topical products include 1% creams, gels, solutions, sprays, and other dosage forms sold under prescription and over-the-counter brands.

The commercial profile is divided:

Segment	Primary use	Commercial attractiveness	Main constraint
Oral 250 mg tablets	Onychomycosis	Low to moderate	Commodity generic pricing and liver-safety monitoring
1% cream	Skin fungal infections	Moderate	Crowded OTC market
1% gel	Skin infections	Moderate	Limited differentiation unless adherence improves
1% spray or solution	Feet and body infections	Moderate to high	Flammability, drying, packaging and preservative issues
Film-forming topical systems	Longer residence and lower dosing frequency	High	Regulatory and performance requirements
Nail-directed systems	Onychomycosis	High	Penetration through nail plate and clinical efficacy
Pediatric or sensitive-skin systems	Dermatophytosis	Moderate	Irritation, preservative and safety constraints

Terbinafine hydrochloride has no meaningful biosimilar opportunity because it is a small-molecule active pharmaceutical ingredient, not a biologic. Commercial entry is based on abbreviated new drug applications, over-the-counter monograph pathways, new drug applications, or reformulation strategies.

What physicochemical properties drive the excipient strategy?

Terbinafine hydrochloride is a lipophilic antifungal salt with limited aqueous solubility relative to many conventional tablet actives. The molecule has a basic amine and strong affinity for lipids and keratinized tissues. These properties create different formulation priorities for oral and topical products.

Oral formulation priorities

The oral dosage form must address:

• Uniform drug distribution at a 250 mg dose.
• Adequate tablet disintegration and dissolution.
• Powder flow and compressibility.
• Stability against moisture and heat.
• Manufacturing cost.
• Low tablet weight and acceptable hardness.
• Consistent bioavailability across generic manufacturers.

Common excipient classes include microcrystalline cellulose or other diluents, sodium starch glycolate or crospovidone as disintegrants, colloidal silicon dioxide as a glidant, magnesium stearate as a lubricant, and film-coating polymers such as hypromellose.

The reference and generic labels show that terbinafine tablets can be manufactured with conventional direct-compression or wet-granulation platforms. Excipients are unlikely to create material clinical differentiation unless they improve dissolution, reduce variability, or support a modified-release product.

Topical formulation priorities

Topical products require a different design approach:

• Solubilizing or dispersing terbinafine hydrochloride.
• Maximizing partitioning into the stratum corneum.
• Limiting evaporation-driven crystallization.
• Controlling irritation and dryness.
• Providing acceptable spreadability.
• Maintaining dose uniformity during repeated use.
• Preserving microbiological quality.
• Matching the intended application site.

Topical vehicles may be aqueous, hydroalcoholic, emulsion-based, gelled, anhydrous, or film-forming. The formulation must balance drug thermodynamic activity against skin tolerability. Excessive use of ethanol, propylene glycol, or penetration enhancers can improve delivery while increasing stinging, erythema, or dryness.

Which excipients are used in terbinafine hydrochloride products?

Oral tablets

Representative excipient systems reported in terbinafine tablet labeling include:

Function	Representative excipients
Diluent and compression aid	Microcrystalline cellulose
Disintegrant	Sodium starch glycolate
Glidant	Colloidal silicon dioxide
Lubricant	Magnesium stearate
Binder or film former	Hypromellose
Opacifier or colorant	Titanium dioxide and approved colorants, depending on manufacturer

The exact composition varies by manufacturer. A generic manufacturer can use a different excipient profile if the product meets quality, bioequivalence, stability, and labeling requirements.

The principal oral excipient risks are not patent risks. They are manufacturing and regulatory risks involving dissolution, impurity formation, tablet robustness, and bioequivalence. Excessive magnesium stearate can slow wetting and dissolution. High levels of hydrophobic glidants or lubricants may be particularly relevant where the formulation already has limited aqueous dissolution.

Creams and emulsions

Representative excipients in topical terbinafine creams include:

• Benzyl alcohol as preservative and solvent.
• Cetyl alcohol and stearyl alcohol as consistency agents.
• Cetyl palmitate as an emollient and structuring material.
• Isopropyl myristate as an emollient and penetration-supporting solvent.
• Polysorbate 60 as an emulsifier.
• Sorbitan monostearate as a co-emulsifier.
• Sodium hydroxide for pH adjustment.
• Purified water as the continuous phase.

Creams are commercially familiar and generally easy to manufacture at scale. Their limitations are slower drying, possible residue, lower consumer convenience, and variable application to interdigital areas or occluded skin.

Gels and hydroalcoholic systems

Gel systems can use:

• Carbomers.
• Hydroxyethylcellulose.
• Hydroxypropylcellulose.
• Propylene glycol.
• Ethanol or isopropanol.
• Polysorbates or other solubilizers.
• Sodium hydroxide or aminomethyl propanol for neutralization.
• Preservatives where required.

A carbomer gel can provide an elegant, non-greasy product, but the formulation must control pH, viscosity, drug crystallization, and compatibility with electrolytes. Neutralization can change terbinafine solubility and may cause precipitation if the drug is not adequately solubilized.

Hydroalcoholic products dry rapidly and can reduce residue. They may be attractive for foot infections, but ethanol and propylene glycol can increase irritation. Flammable-product controls also affect filling, storage, shipping, and packaging.

What formulations are protected by terbinafine hydrochloride patents?

The original terbinafine compound and early product protection are no longer the primary commercial barriers in the United States. Terbinafine hydrochloride is widely marketed by multiple generic manufacturers in oral and topical forms. Current opportunity therefore depends more on formulation engineering, regulatory exclusivity, trademarks, manufacturing know-how, and distribution than on basic active-ingredient patent rights.

Potentially protectable formulation concepts include:

1. Film-forming topical systems.
   A polymeric film can increase residence time, reduce transfer to clothing, and support less frequent application. Candidate polymers include acrylates copolymers, polyvinylpyrrolidone derivatives, cellulose derivatives, and combinations with volatile solvents.

2. Nail-penetrating formulations.
   Penetration enhancers, keratolytic agents, film formers, and nail-compatible solvents may support delivery through the nail plate. A patent position would need to claim a defined composition, concentration range, penetration performance, or clinical regimen.

3. Foam systems.
   Foams can improve application to hair-bearing or large body areas. The main technical barriers are drug solubilization, foam stability, propellant selection, container compatibility, and flammability.

4. Low-irritation systems.
   Reduced ethanol, reduced propylene glycol, alternative preservatives, and skin-barrier-supporting excipients can create a differentiated product for sensitive skin.

5. Extended-release oral products.
   Modified-release tablets or multiparticulates could reduce peak exposure or alter dosing frequency, but the commercial case is weak unless the product demonstrates a clinical or tolerability advantage.

Patent claims based only on using ordinary excipients at routine concentrations are vulnerable to obviousness challenges. Stronger positions generally require a defined performance outcome, such as improved nail penetration, reduced crystallization, enhanced skin retention, reduced dosing frequency, or demonstrated clinical benefit.

When does terbinafine hydrochloride lose exclusivity?

Terbinafine hydrochloride has already lost core U.S. small-molecule exclusivity. The FDA approved Lamisil tablets in the 1990s, and generic terbinafine tablets have been available for many years. The relevant commercial question is no longer loss of primary exclusivity. It is whether a new formulation can obtain independent patent protection or regulatory exclusivity.

Protection type	Current commercial relevance
Original compound patent	Expired or no longer commercially controlling
Original oral product patents	Expired or no longer blocking routine generic entry
Generic oral tablets	Established market with multiple suppliers
Topical cream and gel products	Crowded generic and OTC field
New formulation patents	Potentially relevant if claims cover measurable performance
Method-of-use patents	Potentially relevant for new indications or dosing regimens
Orphan exclusivity	Not a standard basis for current terbinafine products
Biosimilar exclusivity	Not applicable

Patent term for any later-filed formulation generally runs from the relevant nonprovisional filing date, subject to patent-term adjustment and any applicable patent-term extension. A commercial diligence review must distinguish expired legacy patents from live formulation or method-of-use patents.

What is the Orange Book status of terbinafine hydrochloride?

Terbinafine tablets and certain topical products have historically been approved through FDA new drug applications and abbreviated new drug applications. The Orange Book is the controlling source for current listed patents, exclusivity, therapeutic equivalence codes, and approval status.

For mature generic products, the practical Orange Book position is typically:

• Multiple approved generic oral tablets.
• No active compound patent blocking routine generic entry.
• Any relevant listed patents must be assessed product by product and NDA by NDA.
• Topical products may not have the same substitution framework as conventional oral tablets.
• Device, packaging, or formulation protection may sit outside the basic active-ingredient analysis.

FDA Orange Book data should be checked by application number and dosage form because a product may be discontinued while its approval record, patent history, or therapeutic equivalence information remains relevant. The Drugs@FDA database and current Orange Book should be read together.[1,2]

How many patents cover terbinafine hydrochloride?

No single fixed patent count captures the commercial estate. Counts vary depending on whether the search includes:

• Expired compound patents.
• Foreign family members.
• Abandoned applications.
• Formulation patents.
• Packaging and device claims.
• Manufacturing-process patents.
• Method-of-use patents.
• Patent applications that never issued.

For current generic competition, the important conclusion is that terbinafine hydrochloride is not protected by a broad, active composition-of-matter barrier in the way a recently launched branded drug may be. The commercial patent opportunity is narrower and formulation-specific.

A freedom-to-operate review should search claims covering:

• Terbinafine base and hydrochloride salt.
• Specific solvent systems.
• Film-forming polymers.
• Nail penetration.
• Once-daily or single-application regimens.
• Spray, foam, pump, or aerosol delivery.
• Combination products.
• Manufacturing crystallization or particle-size controls.

Which companies are challenging or competing with terbinafine products?

The market includes branded and generic manufacturers. The reference brand Lamisil originated with Novartis, while generic oral tablets and topical products are marketed by numerous companies, including large generic manufacturers and specialty topical companies.

Competition is based on:

• Wholesale acquisition price for oral tablets.
• Retail price and shelf placement for OTC creams and sprays.
• Physician familiarity.
• Package size and dosing convenience.
• Formulation feel and drying time.
• Distribution through pharmacies, mass retailers, and e-commerce.
• Contract manufacturing capacity.
• Ability to support regulatory filings across multiple jurisdictions.

The strongest competitive differentiation is likely in consumer-facing topical products rather than conventional 250 mg tablets.

What patent litigation and Paragraph IV risks affect terbinafine?

Paragraph IV litigation risk is limited for the mature core product but can re-emerge when a company files an ANDA against a product with live listed formulation or method-of-use patents.

For a generic applicant, the key issues are:

• Whether the reference product has current Orange Book-listed patents.
• Whether the ANDA certification is Paragraph III or Paragraph IV.
• Whether the label carves out patented indications or dosing instructions.
• Whether the proposed formulation practices a live composition claim.
• Whether a 30-month stay is triggered by timely litigation.
• Whether a settlement restricts launch timing or supply arrangements.

A topical reformulation may avoid a direct Paragraph IV pathway if it is submitted through a different regulatory route, but it can create direct patent exposure if it relies on an innovator’s protected formulation. Conversely, a novel OTC product may depend more on monograph compliance, NDA review, trademark strategy, and formulation patents.

What manufacturing and intellectual-property barriers exist?

The technical barrier for oral tablets is low. The principal requirements are reliable API supply, particle-size control, blend uniformity, dissolution, tablet coating, and cost-efficient production.

Topical manufacturing has more meaningful process sensitivity. Important controls include:

• API solubilization before emulsification or gel formation.
• Prevention of terbinafine crystallization during storage.
• Control of droplet size in emulsions.
• Control of viscosity and spreadability.
• Homogeneity across tube or pump fills.
• Container-closure compatibility.
• Preservative effectiveness.
• Microbial limits.
• Stability under heat, freeze-thaw, and light exposure.
• Flammability controls for alcohol-containing products.

Manufacturing know-how can be commercially valuable even when patent protection is narrow. A stable high-drug-load solution, a non-stinging film-forming spray, or a nail-compatible formulation may create an operational advantage through process control and product consistency.

How strong is the patent estate for terbinafine hydrochloride?

The estate is weak for the basic active ingredient and conventional oral tablet. It can be moderate for a genuinely differentiated topical delivery system and stronger where the sponsor has:

• A narrow but defensible composition claim.
• Human or ex vivo penetration data.
• Stability data showing reduced crystallization.
• A clinically meaningful dosing advantage.
• Claims covering the commercial container and delivery system.
• Multiple continuation applications with distinct claim scope.
• Protection in the United States, Europe, Japan, and other high-value markets.

A formulation patent has limited value if competitors can achieve the same result with different excipients. The best protection combines composition claims, process claims, use claims, and device or packaging claims.

What licensing deals could create commercial value?

Terbinafine itself is widely available, so licensing the API is unlikely to create meaningful exclusivity. The stronger licensing targets are:

• Film-forming polymer platforms.
• Nail-penetration technologies.
• Foam and spray delivery systems.
• Low-irritation preservative systems.
• Contract development and manufacturing organizations with topical scale-up expertise.
• OTC brands with established dermatology distribution.
• Digital adherence or pharmacy channels linked to treatment courses.

A licensing transaction should separate rights to the active ingredient from rights to the formulation platform, regulatory dossier, trademarks, manufacturing process, and geographic markets. Royalty value will depend more on product differentiation and channel access than on terbinafine API ownership.

What generic launch scenarios exist for terbinafine products?

Conventional oral tablet launch

This is the lowest-risk path technically, but the price environment is competitive. A new entrant needs supply reliability, a competitive cost structure, and sufficient pharmacy or wholesaler access. Patent barriers are generally secondary.

Premium topical launch

A cream, gel, spray, or solution can command a higher price if it improves drying time, ease of application, odor, residue, or dosing convenience. Consumer evidence and retail positioning are critical.

Prescription nail-directed launch

This path offers greater differentiation but requires stronger clinical and penetration evidence. The product must show meaningful benefit in a disease where treatment persistence and nail growth limit outcomes.

OTC reformulation launch

An OTC product can reach consumers without relying on physician prescribing, but it must comply with applicable FDA monograph requirements or obtain an NDA. Labeling, consumer comprehension, packaging, and substantiation become central commercial issues.[3]

How does terbinafine compare with competing antifungals?

Product	Main dosage forms	Key advantage	Excipient opportunity
Terbinafine	Tablet, cream, gel, spray, solution	Strong dermatophyte activity and established awareness	Film-forming, low-irritation and nail-directed products
Clotrimazole	Cream, solution, troche and other forms	Broad availability and low price	Cosmetic elegance and combination delivery
Miconazole	Cream, powder, spray	Broad OTC presence	Moisture control, powder-to-liquid and spray formats
Ketoconazole	Cream, shampoo, foam	Established dermatology use	Scalp delivery and low-irritation vehicles
Ciclopirox	Nail lacquer, cream and other forms	Nail-directed product history	Film-forming nail systems and adherence tools
Efinaconazole	Topical nail solution	Nail-specific commercial positioning	Penetration, applicator and reduced application burden

Terbinafine has a strong position in dermatophyte treatment but faces intense competition in topical OTC products. A differentiated product should solve a specific use problem rather than replicate a standard cream.

What revenue exposure and opportunities exist?

Revenue exposure is highest where a product depends on commodity oral-tablet pricing. A manufacturing disruption or API shortage can affect margins quickly, but product-level pricing power is limited.

Potentially higher-value opportunities include:

• Premium OTC spray or film-forming solution.
• Prescription topical product for difficult-to-treat or recurrent infections.
• Nail-directed product with improved penetration.
• Combination product that improves adherence or addresses mixed clinical presentations.
• Pediatric or sensitive-skin formulation.
• Regional licensing of a topical platform.
• Private-label products for pharmacy and retail chains.

The commercial thesis should focus on gross margin, repeat purchase, retail velocity, and regulatory pathway rather than on the size of the terbinafine molecule market alone.

Key Takeaways

• Terbinafine hydrochloride is a mature generic active with no meaningful current composition-of-matter barrier in routine oral products.
• Conventional 250 mg tablets offer low technical risk but limited differentiation and pricing power.
• Topical delivery provides the strongest commercial opportunity.
• Film-forming, low-irritation, spray, foam, and nail-directed formulations are the most promising excipient-led strategies.
• The central technical risks are solubility, crystallization, skin irritation, nail penetration, preservative performance, and packaging compatibility.
• Current exclusivity analysis must rely on FDA Orange Book and Drugs@FDA records for the specific reference application.
• Paragraph IV risk is product-specific and generally relates to later formulation or method-of-use patents.
• Biosimilar competition is not relevant because terbinafine hydrochloride is a small molecule.
• Licensing value is more likely to reside in delivery technology, manufacturing know-how, brands, and distribution than in the API.
• A defensible patent estate should combine formulation, process, use, and device claims.

FAQs

Can terbinafine hydrochloride be formulated without ethanol?

Yes. Creams, emulsions, aqueous gels, and certain polymeric systems can avoid ethanol. The formulation must still achieve adequate drug solubilization, skin delivery, microbial control, and physical stability.

Which excipient is best for terbinafine hydrochloride nail penetration?

No single excipient is universally optimal. The most credible development approach evaluates solvent systems, keratolytic or permeation-enhancing excipients, film-forming polymers, and applicator design together, followed by validated nail-penetration and clinical studies.

Is terbinafine hydrochloride suitable for a transdermal patch?

A conventional systemic transdermal patch is commercially challenging because dose delivery, skin flux, irritation, and clinical exposure must be demonstrated. A local film or nail-directed patch may be more practical than a systemic patch.

Can a terbinafine topical product qualify for OTC marketing?

Potentially. Eligibility depends on the formulation, concentration, indication, labeling, active-ingredient requirements, and applicable FDA monograph or NDA pathway. A novel delivery system may require an NDA rather than relying solely on an OTC monograph.[3]

What is the main commercial weakness of terbinafine oral tablets?

The main weakness is commodity competition. Multiple manufacturers can produce conventional tablets, making supply reliability and cost control more important than excipient innovation.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (n.d.). Over-the-counter drug review: Monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
4. U.S. National Library of Medicine. (n.d.). DailyMed: Terbinafine hydrochloride tablet and topical product labeling. https://dailymed.nlm.nih.gov/dailymed/
5. U.S. Food and Drug Administration. (1996). Lamisil: Terbinafine hydrochloride prescribing information. FDA approval and labeling records.
6. British Pharmacopoeia Commission. (2024). British Pharmacopoeia: Terbinafine hydrochloride monograph. London, United Kingdom: The Stationery Office.